Background Several clinical trials have shown that immune treatment focus on programmed
death-1 and programmed death-ligand 1 (PD-L1) yields a good clinical efficacy in advanced …

Background Lung adenocarcinoma (AD) is a common variant of non-small cell lung cancer
(NSCLC). Programmed cell death protein 1/programmed cell death ligand 1 (PD1/PD-L1) …

Background The clinicopathologic characteristics of tumors expressing programmed death
(PD-1) ligands (PD-Ls) PD-L1 or PD-L2 and their associations with common driver …

Background Programmed cell death-ligand 1 (PD-L1) is expressed in a group of cancers
that may be suitable targets for specific immunotherapy. This study investigated the …

Purpose: Knowledge regarding programmed death-ligand 1 (PD-L1) expression in lung
cancer is limited. We aim to clarify PD-L1-positive expression in non-small-cell lung cancer …

Objective Programmed death-ligand 1 (PD-L1) is known to be over-expressed in non-small
cell lung cancer (NSCLC). However, the impact of chemotherapy on the altered status of PD …

Background and Objectives Pulmonary pleomorphic carcinoma (PPC) is a rare and
aggressive subtype of lung cancer. Programmed cell death‐ligand 1 (PD‐L1) expression …

Objectives The role of programmed cell death ligand 1 (PD-L1) in non-small cell lung cancer
(NSCLC), especially according to histologic type, remains controversial. The purpose of this …

Introduction The aim of our analysis was to evaluate the prognostic effect of programmed
cell death ligand-1 (PD-L1) expression in patients with non–small cell lung cancer (NSCLC) …

Introduction The clinicopathological features of carcinomas expressing programmed death
ligand 1 (PD-L1) and their associations with common driver mutations, such as mutations in …